Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has completed acquisition of Human Genome Sciences (HGS) for $3.6bn on an equity basis, or approximately $3 billion net of cash and debt. With the acquisition, all ...
Tags: GSK, GlaxoSmithKline, Human Genome Sciences
Human Genome Sciences (HGS) has rejected $2.6bn (£1.6bn) takeover bid offered by GlaxoSmithKline (GSK). GSK offered $13 per share, which is 81% premium to HGS closing price on 18 April 2012, of $7.17 per share. HGS has partnered ...
Tags: HGS, GSK, GlaxoSmithKline
The Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) has supported the clinical benefit of GlaxoSmithKline's raxibacumab to treat inhalational anthrax. In addition, the committee also favoured the ...
Tags: The Anti-Infective Drugs, raxibacumab anti-toxin development programme
GlaxoSmithKline (GSK) has signed a definitive agreement to acquire Human Genome Sciences (HGS) for $14.25 per share in cash. The transaction values HGS at approximately $3.6bn on an equity basis, or approximately $3bn net of cash and ...
Tags: GSK, Human Genome Sciences, HGS